

## Applications

- Treatment of Alzheimer's disease
- Inhibit amyloid- $\beta$  oligomers, oxidative stress, biometals and lipid rafts
- Potential to slow the progression of Alzheimer's disease
- Diagnostic Imaging of beta-amyloid plaques

## Advantages

- Multi-targeted approach to treat Alzheimer's disease
- Studies indicate ligand crosses blood-brain-barrier

## Inventors

[Shijun Zhang, Ph.D](#)

## Contact


T. Allen Morris, Ph.D., MBA  
Associate Director  
[amorris5@vcu.edu](mailto:amorris5@vcu.edu)  
Direct 804-827-2211

## Market Need

Alzheimer's disease (AD) is estimated to afflict 4 million people in the US. The current treatments are limited to symptomatic treatment of cognitive function. The main challenge in AD treatment is its apparent multi-factorial nature. This necessitates the progression from single-target drug development to multi-target.

## Technology Summary

The invention is a series of novel compounds that are useful for the treatment and prevention of Alzheimer's disease. These compounds target multiple risk factors involved in AD including amyloid- $\beta$  oligomers ( $A\beta O$ ) oxidative stress and biometals and cell membrane/lipid rafts. The multifunctional  $A\beta$  oligomerization inhibitors (BMAOIs) strategy targeting CM/LR and other factors involved in the etiology of AD might be an ideal approach to overcome the limits of traditional single-target based approach.



## Technology Status

Patent pending: U.S. rights are available - 13/810,826

Please see journal article- Lenhart *et al.* J. Med. Chem. 2010, 53, 6198–6209.

This technology is available for licensing to industry for further development and commercialization.